annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
982032396 | rs2289658 | rs2289658 | NTRK2 | TT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the TT genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032396 |
982032442 | rs4358872 | rs4358872 | NTRK2 | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032442 |
982032442 | rs4358872 | rs4358872 | NTRK2 | GT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032442 |
982032442 | rs4358872 | rs4358872 | NTRK2 | TT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032442 |
982032477 | rs1948308 | rs1948308 | NTRK2 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032477 |
982032477 | rs1948308 | rs1948308 | NTRK2 | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032477 |
982032477 | rs1948308 | rs1948308 | NTRK2 | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032477 |
982032495 | rs2378676 | rs2378676 | NTRK2 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032495 |
982032495 | rs2378676 | rs2378676 | NTRK2 | AC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032495 |
982032495 | rs2378676 | rs2378676 | NTRK2 | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032495 |
982032512 | rs4877900 | rs4877900 | NTRK2 | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032512 |
982032512 | rs4877900 | rs4877900 | NTRK2 | CT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032512 |
982032512 | rs4877900 | rs4877900 | NTRK2 | TT | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032512 |
982032567 | rs7118900 | rs7118900 | ANKK1 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032567 |
982032567 | rs7118900 | rs7118900 | ANKK1 | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032567 |
982032567 | rs7118900 | rs7118900 | ANKK1 | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032567 |
982032638 | rs2283265 | rs2283265 | DRD2 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032638 |
982032638 | rs2283265 | rs2283265 | DRD2 | AC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AC genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032638 |
982032638 | rs2283265 | rs2283265 | DRD2 | CC | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the CC genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032638 |
982032657 | rs558025 | rs558025 | OPRM1 | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the rs558025 AA genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actiona... | https://www.clinpgx.org/clinicalAnnotation/982032657 |
982032657 | rs558025 | rs558025 | OPRM1 | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the rs558025 AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Ot... | https://www.clinpgx.org/clinicalAnnotation/982032657 |
982032657 | rs558025 | rs558025 | OPRM1 | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the rs558025 GG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Ot... | https://www.clinpgx.org/clinicalAnnotation/982032657 |
982032672 | rs2239622 | rs2239622 | NGF | AA | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AA genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032672 |
982032672 | rs2239622 | rs2239622 | NGF | AG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the AG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032672 |
982032672 | rs2239622 | rs2239622 | NGF | GG | 3 | Dosage | methadone | Heroin Dependence;Opioid-Related Disorders | Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment. | https://www.clinpgx.org/clinicalAnnotation/982032672 |
982032721 | rs2769605 | rs2769605 | null | CC | 3 | Efficacy | lithium;valproic acid | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium or valproic acid as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032721 |
982032721 | rs2769605 | rs2769605 | null | CT | 3 | Efficacy | lithium;valproic acid | Bipolar Disorder | Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032721 |
982032721 | rs2769605 | rs2769605 | null | TT | 3 | Efficacy | lithium;valproic acid | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032721 |
982032727 | rs2071427 | rs2071427 | NR1D1;THRA | CC | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032727 |
982032727 | rs2071427 | rs2071427 | NR1D1;THRA | CT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032727 |
982032727 | rs2071427 | rs2071427 | NR1D1;THRA | TT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032727 |
982032734 | rs6438552 | rs6438552 | GSK3B | AA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the AA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032734 |
982032734 | rs6438552 | rs6438552 | GSK3B | GA | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032734 |
982032734 | rs6438552 | rs6438552 | GSK3B | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the GA or AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032734 |
982032743 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Toxicity | clomipramine;lithium;nefazodone;paroxetine;venlafaxine | Depression | Patients with the AA genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomiprami... | https://www.clinpgx.org/clinicalAnnotation/982032743 |
982032743 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Toxicity | clomipramine;lithium;nefazodone;paroxetine;venlafaxine | Depression | Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomiprami... | https://www.clinpgx.org/clinicalAnnotation/982032743 |
982032743 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Toxicity | clomipramine;lithium;nefazodone;paroxetine;venlafaxine | Depression | Patients with the CC genotype and depression may have a decreased, but not absent, risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's respon... | https://www.clinpgx.org/clinicalAnnotation/982032743 |
982032756 | rs1801260 | rs1801260 | CLOCK | AA | 4 | Toxicity | lithium | Bipolar Disorder | Patients with the AA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors ma... | https://www.clinpgx.org/clinicalAnnotation/982032756 |
982032756 | rs1801260 | rs1801260 | CLOCK | GA | 4 | Toxicity | lithium | Bipolar Disorder | Patients with the GA genotype and Bipolar Disorder may have a decreased, but not absent, risk for sleep disturbances when treated with lithium as compared to patients with the GG genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors ma... | https://www.clinpgx.org/clinicalAnnotation/982032756 |
982032756 | rs1801260 | rs1801260 | CLOCK | GG | 4 | Toxicity | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may have an increased risk for sleep disturbances when treated with lithium as compared to patients with the AA genotype. No association of the G allele is found with response to lithium as compared to the A allele. Other genetic and clinical factors may also influence... | https://www.clinpgx.org/clinicalAnnotation/982032756 |
982032763 | rs1800532 | rs1800532 | TPH1 | GG | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032763 |
982032763 | rs1800532 | rs1800532 | TPH1 | GT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the GT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032763 |
982032763 | rs1800532 | rs1800532 | TPH1 | TT | 3 | Efficacy | lithium | Bipolar Disorder | Patients with the TT genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium. | https://www.clinpgx.org/clinicalAnnotation/982032763 |
982033279 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *1 | 1B | Dosage | acenocoumarol | null | Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “n... | https://www.clinpgx.org/clinicalAnnotation/982033279 |
982033279 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *2 | 1B | Dosage | acenocoumarol | null | Patients carrying CYP2C9*2 allele in combination with a normal, decreased, or no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by DPWG, as... | https://www.clinpgx.org/clinicalAnnotation/982033279 |
982033279 | CYP2C9*1, CYP2C9*2, CYP2C9*3 | null | CYP2C9 | *3 | 1B | Dosage | acenocoumarol | null | Patients carrying CYP2C9*3 allele in combination with a normal function allele, a decreased function allele, or a no function allele may require a lower dose of acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assign... | https://www.clinpgx.org/clinicalAnnotation/982033279 |
982034111 | rs11676382 | rs11676382 | GGCX | CC | 4 | Dosage | acenocoumarol | null | Patients with the CC genotype may need increased dose of warfarin as compared to patients with the GG or CG genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin. | https://www.clinpgx.org/clinicalAnnotation/982034111 |
982034111 | rs11676382 | rs11676382 | GGCX | CG | 4 | Dosage | acenocoumarol | null | Patients with the CG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin. | https://www.clinpgx.org/clinicalAnnotation/982034111 |
982034111 | rs11676382 | rs11676382 | GGCX | GG | 4 | Dosage | acenocoumarol | null | Patients with the GG genotype may need decreased dose of warfarin as compared to patients with the CC genotype, although this is contradicted in most studies. Other genetic and clinical factors may also influence a patient's response to warfarin. | https://www.clinpgx.org/clinicalAnnotation/982034111 |
982034197 | rs1799971 | rs1799971 | OPRM1 | AA | 3 | Dosage | morphine | Pain;Pain, Postoperative | Patients with the rs1799971 AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other ... | https://www.clinpgx.org/clinicalAnnotation/982034197 |
982034197 | rs1799971 | rs1799971 | OPRM1 | AG | 3 | Dosage | morphine | Pain;Pain, Postoperative | Patients with the rs1799971 AG genotype may have increased morphine dose requirements as compared to patients with the AA genotype, but decreased morphine dose requirements as compared to patients with the GG genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recom... | https://www.clinpgx.org/clinicalAnnotation/982034197 |
982034197 | rs1799971 | rs1799971 | OPRM1 | GG | 3 | Dosage | morphine | Pain;Pain, Postoperative | Patients with the rs1799971 GG genotype may have increased morphine dose requirements as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. This drug-variant pair has been assigned a “no recommendation” by CPIC, as it was determined to be not clinically actionable. Other ... | https://www.clinpgx.org/clinicalAnnotation/982034197 |
982034400 | rs2301149 | rs2301149 | KCNIP1;KCNMB1 | CC | 3 | Efficacy | verapamil | Coronary Artery Disease;Hypertension | Patients with the CC genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and... | https://www.clinpgx.org/clinicalAnnotation/982034400 |
982034400 | rs2301149 | rs2301149 | KCNIP1;KCNMB1 | CG | 3 | Efficacy | verapamil | Coronary Artery Disease;Hypertension | Patients with the CG genotype and hypertensive coronary artery disease may have a decreased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's blood pressure and... | https://www.clinpgx.org/clinicalAnnotation/982034400 |
982034400 | rs2301149 | rs2301149 | KCNIP1;KCNMB1 | GG | 3 | Efficacy | verapamil | Coronary Artery Disease;Hypertension | Patients with the GG genotype and hypertensive coronary artery disease may have an increased risk of mortality, nonfatal myocardial infarction, or nonfatal stroke when treated with verapamil as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's blood press... | https://www.clinpgx.org/clinicalAnnotation/982034400 |
982034831 | rs1045642 | rs1045642 | ABCB1 | AA | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982034831 |
982034831 | rs1045642 | rs1045642 | ABCB1 | AG | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the AG genotype and colorectal cancer may have a longer period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982034831 |
982034831 | rs1045642 | rs1045642 | ABCB1 | GG | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the GG genotype and colorectal cancer did not have a statistically significant different period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment... | https://www.clinpgx.org/clinicalAnnotation/982034831 |
982034869 | rs1128503 | rs1128503 | ABCB1 | AA | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the AA genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982034869 |
982034869 | rs1128503 | rs1128503 | ABCB1 | AG | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982034869 |
982034869 | rs1128503 | rs1128503 | ABCB1 | GG | 3 | Efficacy | oxaliplatin | Colorectal Neoplasms | Patients with the GG genotype and colorectal cancer may have a decreased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment. | https://www.clinpgx.org/clinicalAnnotation/982034869 |
982034888 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | acetylcholine | null | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with acetylcholine as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic ... | https://www.clinpgx.org/clinicalAnnotation/982034888 |
982034888 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | acetylcholine | null | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTG... | https://www.clinpgx.org/clinicalAnnotation/982034888 |
982034888 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | acetylcholine | null | Patients with the del/del genotype may experience less vasodilation when treated with acetylcholine as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/982034888 |
982034899 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | nitroprusside | null | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may experience greater vasodilation when treated with nitroprusside as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or del/del genotype. Other genetic ... | https://www.clinpgx.org/clinicalAnnotation/982034899 |
982034899 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | nitroprusside | null | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may experience greater vasodilation as compared to patients with the del/del genotype but lesser vasodilation as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTG... | https://www.clinpgx.org/clinicalAnnotation/982034899 |
982034899 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | nitroprusside | null | Patients with the del/del genotype may experience less vasodilation when treated with nitroprusside as compared to patients with ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del or ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/982034899 |
982035482 | rs17880887 | rs17880887 | VKORC1 | GG | 3 | Dosage | warfarin | null | Patients with the GG genotype may require lower dose of warfarin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes. | https://www.clinpgx.org/clinicalAnnotation/982035482 |
982035482 | rs17880887 | rs17880887 | VKORC1 | GT | 3 | Dosage | warfarin | null | Patients with the GT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes. | https://www.clinpgx.org/clinicalAnnotation/982035482 |
982035482 | rs17880887 | rs17880887 | VKORC1 | TT | 3 | Dosage | warfarin | null | Patients with the TT genotype may require higher dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dose. This variant rs17880887 is part of VKORC1 H8 and H9 haplotypes. | https://www.clinpgx.org/clinicalAnnotation/982035482 |
982035703 | rs2884737 | rs2884737 | VKORC1 | AA | 2A | Dosage | warfarin | null | Patients with the rs2884737 AA genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements. | https://www.clinpgx.org/clinicalAnnotation/982035703 |
982035703 | rs2884737 | rs2884737 | VKORC1 | AC | 2A | Dosage | warfarin | null | Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements. | https://www.clinpgx.org/clinicalAnnotation/982035703 |
982035703 | rs2884737 | rs2884737 | VKORC1 | CC | 2A | Dosage | warfarin | null | Patients with the rs2884737 CC genotype may require lower dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence warfarin dosage requirements. | https://www.clinpgx.org/clinicalAnnotation/982035703 |
982036238 | rs1045642 | rs1045642 | ABCB1 | AA | 3 | Other | verapamil | null | Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036238 |
982036238 | rs1045642 | rs1045642 | ABCB1 | AG | 3 | Other | verapamil | null | Patients with the AG genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036238 |
982036238 | rs1045642 | rs1045642 | ABCB1 | GG | 3 | Other | verapamil | null | Patients with the GG genotype may have decreased metabolism of verapamil as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036238 |
982036249 | rs2032582 | rs2032582 | ABCB1 | AA | 3 | Other | verapamil | null | Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036249 |
982036249 | rs2032582 | rs2032582 | ABCB1 | AC | 3 | Other | verapamil | null | Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036249 |
982036249 | rs2032582 | rs2032582 | ABCB1 | CC | 3 | Other | verapamil | null | Patients with the CC genotype may have decreased metabolism of verapamil as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil. | https://www.clinpgx.org/clinicalAnnotation/982036249 |
982036328 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC | 3 | Efficacy | spironolactone | Heart Failure | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to... | https://www.clinpgx.org/clinicalAnnotation/982036328 |
982036328 | rs1799752 | rs1799752 | ACE | ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del | 3 | Efficacy | spironolactone | Heart Failure | Patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del genotype may be associated with improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the del/del genotype. Other gene... | https://www.clinpgx.org/clinicalAnnotation/982036328 |
982036328 | rs1799752 | rs1799752 | ACE | del/del | 3 | Efficacy | spironolactone | Heart Failure | Patients with the del/del genotype may have less improvement in left ventricular ejection fraction, end-systolic and end-diastolic volume in people with chronic heart failure treated with spironolactone as compared to patients with the ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGA... | https://www.clinpgx.org/clinicalAnnotation/982036328 |
982036556 | rs4148416 | rs4148416 | ABCC3 | CC | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the CC genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036556 |
982036556 | rs4148416 | rs4148416 | ABCC3 | CT | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the CT genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036556 |
982036556 | rs4148416 | rs4148416 | ABCC3 | TT | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the TT genotype and osteosarcoma have not been studied. However, patients carrying the T allele (CT genotype) may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients homozygous for the C allele. Other genetic and... | https://www.clinpgx.org/clinicalAnnotation/982036556 |
982036595 | rs4148737 | rs4148737 | ABCB1 | CC | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the CC genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036595 |
982036595 | rs4148737 | rs4148737 | ABCB1 | CT | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinica... | https://www.clinpgx.org/clinicalAnnotation/982036595 |
982036595 | rs4148737 | rs4148737 | ABCB1 | TT | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the TT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036595 |
982036604 | rs1128503 | rs1128503 | ABCB1 | AA | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the AA genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036604 |
982036604 | rs1128503 | rs1128503 | ABCB1 | AG | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinica... | https://www.clinpgx.org/clinicalAnnotation/982036604 |
982036604 | rs1128503 | rs1128503 | ABCB1 | GG | 3 | Efficacy | cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine | Osteosarcoma | Patients with the GG genotype and osteosarcoma may have an increased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response. | https://www.clinpgx.org/clinicalAnnotation/982036604 |
982037307 | rs5918 | rs5918 | ITGB3 | CC | 4 | Efficacy | aspirin | Acute coronary syndrome;Coronary Artery Disease | Patients with the CC genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.clinpgx.org/clinicalAnnotation/982037307 |
982037307 | rs5918 | rs5918 | ITGB3 | CT | 4 | Efficacy | aspirin | Acute coronary syndrome;Coronary Artery Disease | Patients with the CT genotype may be less likely to respond to aspirin as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.clinpgx.org/clinicalAnnotation/982037307 |
982037307 | rs5918 | rs5918 | ITGB3 | TT | 4 | Efficacy | aspirin | Acute coronary syndrome;Coronary Artery Disease | Patients with the TT genotype may be more likely to respond to aspirin as compared to patients with the CC or CT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin. | https://www.clinpgx.org/clinicalAnnotation/982037307 |
982037368 | rs5918 | rs5918 | ITGB3 | CC | 3 | Efficacy | clopidogrel | Coronary Artery Disease;Myocardial Infarction | Patients with the CC genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogr... | https://www.clinpgx.org/clinicalAnnotation/982037368 |
982037368 | rs5918 | rs5918 | ITGB3 | CT | 3 | Efficacy | clopidogrel | Coronary Artery Disease;Myocardial Infarction | Patients with the CT genotype may have a decreased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with TT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to clopidogr... | https://www.clinpgx.org/clinicalAnnotation/982037368 |
982037368 | rs5918 | rs5918 | ITGB3 | TT | 3 | Efficacy | clopidogrel | Coronary Artery Disease;Myocardial Infarction | Patients with the TT genotype may have an increased antiplatelet effect to a 300 or 600 mg loading dose clopiodgrel as compared to patients with CC or CT genotype. Other studies found no association with differences in platelet inhibition. Other genetic and clinical factors may also influence a patient's response to cl... | https://www.clinpgx.org/clinicalAnnotation/982037368 |
982037378 | rs1126643 | rs1126643 | ITGA2 | CC | 3 | Efficacy | aspirin;clopidogrel | Coronary Artery Disease;Coronary Disease;Myocardial Infarction | Patients with the CC genotype may be more likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CT or TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037378 |
982037378 | rs1126643 | rs1126643 | ITGA2 | CT | 3 | Efficacy | aspirin;clopidogrel | Coronary Artery Disease;Coronary Disease;Myocardial Infarction | Patients with the CT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037378 |
982037378 | rs1126643 | rs1126643 | ITGA2 | TT | 3 | Efficacy | aspirin;clopidogrel | Coronary Artery Disease;Coronary Disease;Myocardial Infarction | Patients with the TT genotype may be less likely to respond to treatment with aspirin and clopidogrel as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to aspirin and clopidogrel. | https://www.clinpgx.org/clinicalAnnotation/982037378 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.